Skip to content
Prof. Dr. Mustafa Özdoğan · Medical Oncologist

A new treatment strategy in cancer has been discovered: collateral lethality!

A new treatment strategy in cancer has been discovered: collateral lethality!

Among the 10 hallmarks of cancer are abnormalities in genetic structure. To multiply rapidly and spread to other tissues, cancer cells silence growth-inhibiting tumor suppressor genes . However, in doing so, genes surrounding the tumor suppressor gene are also inactivated. This is called collateral lethality . Recent research has shown that collateral lethality may be an effective strategy for cancer treatment. In seeking an equivalent in our language, terms such as “secondary / side / multilateral lethality” emerge.

Tumor suppressor genes are the most important protectors against cancer formation. When they are damaged, a cell begins to become cancerous. In most human cancers, tumor suppressor genes have been found to undergo mutation . It had been established that when cancer cells silence their tumor suppressor genes, they also silence surrounding genes. The diagram below shows the mechanism of collateral lethality in cancer.

Collateral

Diagram explanation: In normal cells, two different pathways perform the same biochemical process. Inactivating one pathway does not prevent the biochemical process. In cancer cells, however, because one of the genes controlling the same biochemical pathway is silenced, the cancer cell becomes dependent on the other gene. This offers us an effective drug target. Inhibiting the activity of this gene or the enzyme it encodes may inhibit cancer cell growth.

Naturepublished a study indicating that, particularly in pancreatic cancer , collateral lethality may be an effective treatment strategy. The study investigated collateral lethality in pancreatic cancer. Of every 3 pancreatic cancers, 1 contains a mutated SMAD4 gene; the activity of neighboring genes was examined. According to the research results:

Neighboring SMAD4, the ME2 gene was also found to be silenced. ME2 is the gene that enables production of enzymes required for cancer cells’ energy generation. Cancer cells find a solution by keeping the ME3 gene active. Treatments targeting ME3 may therefore enable cancer cells to be destroyed.

What does this study mean clinically?

  • A new treatment strategy in cancer has been identified. By identifying the collateral lethality mechanism in each cancer type, new drug targets may be discovered.
  • This study has once again demonstrated the importance of genes in treating cancer effectively.

Sources

1- Muller, Florian L. et al.
Collateral Lethality: A New Therapeutic Strategy in Oncology.
Trends in Cancer , Volume 1 , Issue 3 , 161 - 173.

2- Prasenjit Dey, Joelle Baddour, Florian Muller et al.
Genomic deletion of malic enzyme 2 confers collateral lethality in pancreatic cancer.
Nature 542, 119-123 (February 2017)

Appointment request

DROZDOGAN AI

Explore this article together

Ask about the article and read answers alongside published sources from our site.

DROZDOGAN AI

Drozdogan Assistant

A new treatment strategy in cancer has been discovered: collateral lethality!

Ask about the article and read answers alongside published sources from our site.

Conversation and privacy information

Drozdogan Assistant answers this conversation. Authorized site administrators may review it for quality. Do not share personal information.

Replies use OpenAI infrastructure. Questions and replies are processed by that service; conversation records are stored on our site. Do not share identifying, contact or personal health information.

0 / 1000

For information only; no personal diagnosis or treatment advice.

Related articles

Explore other articles on this topic.

Stay informed

Receive new articles and scientific updates by email.

Google Analytics runs on public pages independently of this window and may use analytics cookies. Your choice here controls external services only.

Cookie policy